Translational Pharmacogenomics: Discoveries to Clinical Implementation

Translational Pharmacogenomics: Discoveries to Clinical Implementation

by Brittney H. Davis, PharmD

Life & Natural Systems Medicine & Health MMedicine and NursingMKGPharmacology
🎙 Brittney H. Davis, PharmD 👥 884 📅 September 17, 2025 ⏱ 37 min 👁 320 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

pharmacogenomicsdrug responseCBDepilepsyclinical implementation

Summary

Dr. Brittney Davis presents her work in translational pharmacogenomics, focusing on identifying genetic predictors of drug response and implementing these findings in clinical practice. She begins by highlighting the problem of variable medication response, noting that 38-75% of patients do not respond to their first medication and that adverse drug events are a leading cause of death. She explains basic pharmacology concepts (pharmacokinetics and pharmacodynamics) and how genetic variation affects drug metabolism and targets. Her research on CBD response in treatment-resistant epilepsy is detailed: using a comprehensive pharmacogenomic approach, she identified 29 genes associated with response, many of which are co-expressed, and variants affecting expression of potential targets like GPR18 and HTR3E. She emphasizes the importance of human-specific biology. She then discusses clinical implementation, relying on resources like CPIC and FDA guidelines, and presents the Alabama Genomic Health Initiative (AGHI) which has enrolled over 10,000 participants and now includes pharmacogenomic testing. The talk concludes with the goal of preemptive testing to guide prescribing.

163 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable insights into the challenges and opportunities in pharmacogenomics. The argumentation is solid, based on the speaker’s own research and established resources. She effectively demonstrates the limitations of candidate gene studies and the potential of comprehensive approaches. The use of specific examples, such as the CBD study, strengthens the argument. However, as a seminar, it lacks detailed statistical methods and may oversimplify some concepts.

76 words

Title / Content Match

The title accurately reflects the content, which covers translational pharmacogenomics from genetic discovery to clinical implementation.

Quality & Reliability

8/10

The talk is given by a PharmD and assistant professor with direct involvement in the research presented. It references established resources like CPIC and FDA, and describes peer-reviewed studies. However, as a seminar presentation, it lacks detailed methodological transparency and independent verification.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • CPIC Guidelines — Referenced as a key resource for gene-drug guidelines.
  • FDA Pharmacogenomics Table — Referenced as a resource for pharmacogenomic associations in drug labeling.
  • PharmGKB — Mentioned as a comprehensive resource for pharmacogenomic knowledge.

Concurring Sources

Contribution & Novelties

The talk provides an original perspective on applying a comprehensive pharmacogenomic approach to drugs with unclear mechanisms, exemplified by the CBD study. It highlights the potential of co-expression networks and human-specific genes in understanding drug response. The speaker also emphasizes the importance of translating discoveries into clinical practice, as demonstrated by the AGHI initiative.

Pour aller plus loin :

  • Pharmacogenomics — Overview of the field.
  • Cannabidiol — Background on CBD and its medical uses.
  • CPIC — Clinical Pharmacogenetics Implementation Consortium.
  • PharmGKB — Comprehensive pharmacogenomic resource.

85 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating a well-balanced presentation accessible to a broad scientific audience.

Reliability 8/10